For instance, NKp46-deficient mice exhibit impaired tumour control in lymphoma and melanoma models (101–104), while reduced NKp30 and NKp46 expression in patients with leukaemia or cervical cancer correlates with poorer outcomes (105–107). This evidence concerns the gene NCR3 and neoplasm.